BioSpace News Archive

AMRA and BioTelemetry Research Announced today the formation of an exclusive alliance for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) clinical trials.

Anatara Lifesciences is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors this week by CEO - chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

BerGenBio announces that the randomised Phase 1b/2 clinical study of BGB324 in combination with either the MAP kinase inhibitors MEKINIST (trametinib) plus TAFINLAR (dabrafenib) or the immune checkpoint inhibitor KEYTRUDA (pembrolizumab) in patients with advanced melanoma is recruiting well at four sites in Norway and reports a favourable safety profile.

Nexus Pharma announced today the immediate availability in the United States of Procainamide HCL Injection, USP.

Corbus Pharmaceuticals, a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors.

The new investment was led by Nan Fung Life Sciences and also included investments from New Enterprise Associates NEA, Charles and Helen Schwab, and Maveron.

EchoPixel announced today that it has closed an $8.5M Series A financing.

n a study in today’s issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels to proliferate.

Konica Minolta and Innovation Network Corporation of Japan announced the close of their joint acquisition of Ambry Genetics Corporation on October 19, 2017 (JST).

Alkermes plc will host a conference call and webcast presentation at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, Oct. 26, 2017, to discuss the company’s third quarter 2017 financial results.